Evotec Presents its Fragment Screening Technology at Two Key Conferences
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Evotec AG will be presenting at two conferences on its fragment screening technology. Presentations will be given at Screening, MedChem and ADMET Europe on 24th February in Berlin, Germany and at the Molecular Medicine Tri-Conference in San Francisco, USA on 25th February.
Evotec’s fragment screening platform, EVOlution™ combines ultra sensitive bioassay and high field NMR screening technologies with a highly diverse library of 40,000 fragments. By combining the two detection technologies with a large pool of diverse fragments Evotec can identify fragment hits against a range of targets including protein-protein interactions. During the conferences Evotec will illustrate the use of its technology in finding fragment hits for targets of high pharmaceutical interest.
During the Screening, MedChem and ADMET Europe conference in Berlin, Evotec will discuss the identification of novel MAPKAP Kinase 2 (MK2) Inhibitors and will also present a poster entitled, ‘Fragment-based Drug Discovery by NMR: Reaping the benefits of orthogonal screening approaches to validate hit compounds’.
At the Molecular Medicine Tri-Conference, Evotec will present on the use of its fragment screening technology to discover novel inhibitors for prominent targets, in particular PDE10a, BACE-1 and MK2.
Evotec will also be exhibiting two posters entitled, ‘The crystal structure of human phosphodiesterase 10a (hPDE10a) in complex with papaverine’; and ‘Identification of fragment inhibitors of phosphodiesterase 10a (PDE10a)’.
Evotec’s fragment screening platform, EVOlution™ combines ultra sensitive bioassay and high field NMR screening technologies with a highly diverse library of 40,000 fragments. By combining the two detection technologies with a large pool of diverse fragments Evotec can identify fragment hits against a range of targets including protein-protein interactions. During the conferences Evotec will illustrate the use of its technology in finding fragment hits for targets of high pharmaceutical interest.
During the Screening, MedChem and ADMET Europe conference in Berlin, Evotec will discuss the identification of novel MAPKAP Kinase 2 (MK2) Inhibitors and will also present a poster entitled, ‘Fragment-based Drug Discovery by NMR: Reaping the benefits of orthogonal screening approaches to validate hit compounds’.
At the Molecular Medicine Tri-Conference, Evotec will present on the use of its fragment screening technology to discover novel inhibitors for prominent targets, in particular PDE10a, BACE-1 and MK2.
Evotec will also be exhibiting two posters entitled, ‘The crystal structure of human phosphodiesterase 10a (hPDE10a) in complex with papaverine’; and ‘Identification of fragment inhibitors of phosphodiesterase 10a (PDE10a)’.
